Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri 63110, USA.
J Thorac Oncol. 2010 Jan;5(1):23-8. doi: 10.1097/JTO.0b013e3181c41e8d.
The median age of patients with newly diagnosed non-small cell lung cancer (NSCLC) at presentation is 71 years. We conducted an analysis of Surveillance, Epidemiology, and End Results data to assess whether the presentation and outcomes of NSCLC in younger patients (age < or =40 years) are different from that in older patients (age >40 years).
We obtained the demographic, clinical, and outcomes data for all patients diagnosed with NSCLC from 1988 to 2003 in the Surveillance, Epidemiology, and End Results registry. Patients were grouped by age at diagnosis into younger than or equal to 40 years (younger cohort) or older than 40 years (older cohort).
During the period analyzed, we identified 2775 patients with NSCLC in the younger cohort and 236,313 patients in the older cohort. Compared with the older group, the younger group had greater proportion of African Americans (19.2% versus 10.9%; p < 0.0001), Asian or Pacific Islander (10.3% versus 5.9%; p < 0.0001), women (48.7% versus 41.9%; p < 0.0001), and patients with stage IV disease (57.4% versus 43.0%; p < 0.0001). Adenocarcinoma was more common in younger patients than in the older patients (57.5% versus 45.2%; p < 0.0001). Squamous cell carcinoma was less prevalent in the younger cohort than in older cohort (12.5% versus 26.4%; p < 0.0001). Five-year overall survival and cancer specific survival were significantly better for younger patients than for older patients across all stages.
There is a greater representation of African Americans, Asians or Pacific Islanders, women, and adenocarcinoma histology in the younger cohort of patients with NSCLC compared with the older cohort. Despite presenting with stage IV disease more often, the overall and cancer-specific survivals are better in younger cohort than in the older cohort.
新诊断的非小细胞肺癌（NSCLC）患者的中位发病年龄为 71 岁。我们对监测、流行病学和最终结果数据进行了分析，以评估年轻患者（年龄≤40 岁）与老年患者（年龄＞40 岁）的 NSCLC 表现和结局是否不同。
我们从监测、流行病学和最终结果登记处获取了 1988 年至 2003 年间所有诊断为 NSCLC 的患者的人口统计学、临床和结局数据。根据诊断时的年龄将患者分为≤40 岁（年轻组）或＞40 岁（老年组）。
在分析期间，我们在年轻组中发现了 2775 例 NSCLC 患者，在老年组中发现了 236313 例 NSCLC 患者。与老年组相比，年轻组中非洲裔美国人的比例更高（19.2%比 10.9%；p<0.0001），亚洲人或太平洋岛民（10.3%比 5.9%；p<0.0001），女性（48.7%比 41.9%；p<0.0001）和 IV 期疾病患者（57.4%比 43.0%；p<0.0001）。年轻患者中腺癌比老年患者更常见（57.5%比 45.2%；p<0.0001）。年轻组中鳞状细胞癌的发病率低于老年组（12.5%比 26.4%；p<0.0001）。所有分期的年轻患者的 5 年总生存率和癌症特异性生存率均明显优于老年患者。
与老年患者相比，年轻患者中非小细胞肺癌患者中非洲裔美国人、亚洲人或太平洋岛民、女性和腺癌组织学的比例更高。尽管年轻患者更常出现 IV 期疾病，但总体生存率和癌症特异性生存率均优于老年患者。
